Q-omics provides the consensus-scored DACT1 profile across patient tissues and cancer cell-line models. DACT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DACT1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, DACT1 RNA expression shows 18,524 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, THCA, and BRCA as cancer lineages where DACT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DACT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DACT1 survival associations across molecular data types. DACT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DACT1 RNA expression–survival associations across cancer types. High DACT1 expression shows unfavorable associations in MESO, ACC, BLCA, THCA and CESC, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DACT1 RNA expression.
This table summarizes DACT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DACT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DACT1 shows lower tumor expression in THCA, KIRP and BLCA and higher tumor expression in HNSC, STAD and BRCA. The THCA box plot shows higher DACT1 RNA expression in normal versus tumor tissue (log2 FC = −1.687, t-test p < 0.001).
This table shows molecular features associated with DACT1 in patient tissues and cancer cell lines. In patient samples, DACT1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DACT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
